The Information Technology (IT) Infrastructure of the Multicenter Archipelago of Ovarian Cancer Research Biobank: A Potential Blueprint for Other Biobanks.

Autor:	Zelisse HS; Department of Pathology, Cancer Center Amsterdam, Amsterdam Reproduction & Development Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., de Ridder S; Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., van Gent MDJM; Department of Gynaecologic Oncology, Centre for Gynaecologic Oncology Amsterdam, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Mom CH; Department of Gynaecologic Oncology, Centre for Gynaecologic Oncology Amsterdam, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Wisman GBA; Department of Gynaecologic Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Roes EM; Department of Gynecologic Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Reyners AKL; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Piek JM; Department of Obstetrics and Gynaecology, Catharina Hospital, Catharina Cancer Institute, Eindhoven, the Netherlands., Nieuwenhuyzen-de Boer GM; Department of Gynaecology and Obstetrics, Albert Schweitzer Hospital, Dordrecht, the Netherlands., Lok CAR; Department of Gynaecological Oncology, Centre for Gynaecologic Oncology Amsterdam, Antoni van Leeuwenhoek, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Kroon CD; Department of Obstetrics and Gynaecology, Leiden University Medical Center, Leiden, the Netherlands., Kooreman LFS; Department of Pathology and GROW, School for Oncology & Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands., Janssen MJ; Department of Gynecological Oncology, Medisch Spectrum Twente, Enschede, the Netherlands., Jansen MP; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Horlings HM; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Collée M; Department of Clinical Genetics, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Broeks A; Department of CFMPB (Core Facility - Molecular Pathology and Biobanking), The Netherlands Cancer Institute, Amsterdam, the Netherlands., Boere IA; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Bart J; Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., van Altena AM; Department of Obstetrics & Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands., Heeling M; Department of Pathology, Cancer Center Amsterdam, Amsterdam Reproduction & Development Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Stoter IM; Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Voorham QJ; Palga Foundation, Houten, the Netherlands., van de Vijver MJ; Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Dijk F; Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Belien JAM; Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Jazyk:	angličtina
Zdroj:	Biopreservation and biobanking [Biopreserv Biobank] 2024 Apr 29. Date of Electronic Publication: 2024 Apr 29.
DOI:	10.1089/bio.2023.0118
Abstrakt:	Objective: Biobanks play a crucial role in fundamental and translational research by storing valuable biomaterials and data for future analyses. However, the design of their information technology (IT) infrastructures is often customized to specific requirements, thereby lacking the ability to be used for biobanks comprising other (types of) diseases. This results in substantial costs, time, and efforts for each new biobank project. The Dutch multicenter Archipelago of Ovarian Cancer Research (AOCR) biobank has developed an innovative, reusable IT infrastructure capable of adaptation to various biobanks, thereby enabling cost-effective and efficient implementation and management of biobank IT systems. Methods and Results: The AOCR IT infrastructure incorporates preexisting biobank software, mainly managed by Health-RI. The web-based registration tool Ldot is used for secure storage and pseudonymization of patient data. Clinicopathological data are retrieved from the Netherlands Cancer Registry and the Dutch nationwide pathology databank (Palga), both established repositories, reducing administrative workload and ensuring high data quality. Metadata of collected biomaterials are stored in the OpenSpecimen system. For digital pathology research, a hematoxylin and eosin-stained slide from each patient's tumor is digitized and uploaded to Slide Score. Furthermore, adhering to the Findable, Accessible, Interoperable, and Reusable (FAIR) principles, genomic data derived from the AOCR samples are stored in cBioPortal. Conclusion: The IT infrastructure of the AOCR biobank represents a new standard for biobanks, offering flexibility to handle diverse diseases and types of biomaterials. This infrastructure bypasses the need for disease-specific, custom-built software, thereby being cost- and time-effective while ensuring data quality and legislative compliance. The adaptability of this infrastructure highlights its potential to serve as a blueprint for the development of IT infrastructures in both new and existing biobanks.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu